Publications

Publications Related to AVISE CTD / AVISE Lupus / AVISE CB-CAPs

Ramsey-Goldman, R., et al. (2019).  Complement activation occurs in patients with probable systemic lupus erythematosus and may predict progression to ACR classified SLE.  Arthritis & Rheumatology.

Wallace, D., et al. (2016). Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products. Lupus Science & Medicine. 

Putterman, C., et al. (2014). Cell bound complement activation products in systemic lupus erythematosus. Lupus Science & Medicine.

Alexander, R.V., et al. (2021). A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus. Lupus Science & Medicine.

Liang, E., et al. (2020). Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression. Lupus Science & Medicine.

Wallace, D., et al. (2019). Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. Lupus Science & Medicine.

Mossell, J., et al. (2016). The AVISE Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus. The Open Rheumatology Journal.

Clarke, A., et al. (2020). Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using a Multivariate Assay Panel (MAP). ACR Open Rheumatology.

Dervieux, T., et al. (2017) Validation of multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus. Journal of Immunological Methods.

Mosca, M., et al. (2019). How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. Arthritis & Rheumatology.

Meacock, R., et al. (2013). The humanistic and economic burden of systemic lupus erythematosus: A systematic review. Pharmacoeconomics.

Lamichhane, D., et al. (2016). Probable systemic lupus erythematosus with cell-bound complement activation products (CB-CAPs). Lupus.

Kao, A., et al. (2010). Erythrocyte C3d and C4d for Monitoring Disease Activity in Systemic Lupus Erythematosus. Arthritis and Rheumatology.

AVISE SLE Monitor is indicated for the ongoing assessment of SLE disease activity

Svenungsson, E., et al. (2020). Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus. Rheumatology.

Petri, M.A., et al. (2019). Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE Lupus Science & Medicine. Lupus Science and Medicine.

Merrill, J.T., et al. (2018). Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Science & Medicine

Mahler, M., et al. (2017). Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring of Systemic Lupus Erythematosus. Journal of Immunology Research.

Buyon, J., et al. (2016). Reduction in erythrocyte-bound complement activation products and titers of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus. Lupus Science & Medicine.

Orbai, A.M., et al. (2015). Anti-C1q antibodies in systemic lupus erythematosus. Lupus.

Kao, A.H., et. al. (2014). Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus. Translational Stroke Research.

Akhter, E., et al. (2012). Anti-C1q antibodies have a higher correlation with flares of lupus nephritis than other serum markers. Lupus.

Kao, A., et al. (2010). Erythrocyte C3d and C4d for Monitoring Disease Activity in Systemic Lupus Erythematosus. Arthritis and Rheumatology.

Kao, A.H., et al. (2010). Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis & Rheumatism.

Liu, C.C., et al. (2009). Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus. Clinical and Translational Science.

Yang, D., et al. (2009). The usefulness of erythrocyte-bound C4d as a biomarker to predict disease activity in patients with systemic lupus erythematosus. Rheumatology.

Manzi, S., et al. (2004). Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis & Rheumatism.

Dervieux, T., et al. (2017). Validation of multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus. Journal of Immunological Methods.

Ramsey-Goldman, R., et al. (2017). Cell-bound complement activation products in SLE. Lupus Science and Medicine.

Ahearn, J., et al. (2017). Cell-bond complement activation products as lupus biomarkers: diagnosis, monitoring and stratification. Expert Review of Clinical Rheumatology.

PC4d is indicated for diagnosed SLE patients as a marker associated with thrombosis.

Svenungsson, E., et al. (2020). Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus. Rheumatology.

Petri, M., et al. (2019). Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE Lupus Science & Medicine. Lupus Science and Medicine.

Kao, A., et al. (2014). Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus. Translational Stroke Research.

Dervieux, T., et al. (2019). Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept. Ann Rheum Dis.

Takahashi, C., et al. (2017). Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD Open.

Dervieux, T., et al. (2013). Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis. Annals of the Rheumatic Diseases. 

Dervieux, T., et al. (2010). Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology.

Dervieux, T., et al. (2006). Pharmacogenomic and Metabolic Biomarkers in the Folate Pathway and Their Association With Methotrexate Effects During Dosage Escalation in Rheumatoid Arthritis. Arthritis and Rheumatology.

Dervieux , T., et al. (2005). Pharmacogentic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentered cross-sectional observation study. Annals of the Rheumatic Diseases.

Brady, K., et al. (2019). Transition of Methotrexate Polyglutamate Drug Monitoring Assay from Venipuncture to Capillary Blood-Based Collection Method in Rheumatic Diseases. The Journal of Applied Laboratory Medicine.

Braun, J. (2011). Methotrexate: Optimizing the Efficacy in Rheumatoid Arthritis. Therapeutic Advances in Musculoskeletal Disease. Therapeutic Advances in Musculoskeletal Disease.

Kremer J. et al. (2004). Toward a Better Understanding of Methotrexate. Arthritis & Rheumatology.

AVISE HCQ is indicated for SLE patients receiving Hydroxychloroquine therapy as an objective measure of drug exposure.

Petri, M., et al. (2020). Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy. Arthritis & Rheumatology.

Costedoat-Chalumeau, N. (2019). A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. American Society for Clinical Pharmacology and Therapeutics.

Costedoat-Chalumeau, N., et al. (2013). Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Annals of the Rheumatic Diseases.

Qu, Y., et al. (2017). Capillary blood collected on volumetric absorptive microsampling (VAMS) device for monitoring hydroxychloroquine in rheumatoid arthritis patients. Journal of Pharmaceutical and Biomedical Analysis.

Durcan, L., et al. (2015). Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. The Journal of Rheumatology.

Arriens, C., et al. (2020). Cell-bound complement activation products associate with lupus severity in SLE. Lupus Science & Medicine. Lupus Science & Medicine.

Hui-Yen, J., et al. (2018). Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity. Lupus.

Dervieux, T., et al. (2019). Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept. Ann Rheum Dis.

Weinstein, A., et al. (2019). Reevaluating Serologic Markers of Poor Prognostic Factors in Rheumatoid Arthritis. The Journal of Rheumatology.

Shi, J., et al. (2011). Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. PNAS.

Petri, et al. 2020. Role of Platelet C4d in Thrombosis and Lupus Nephritis. Arthritis Rheumatol.

Gartshteyn Y., et al. 2020. Platelet-bound C4d Is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE. Arthritis Rheumatol.

Petri M., et al. 2020. Agreement of Hydroxychloroquine Blood Levels Between a University and Commercial Laboratory. Arthritis Rheumatol.

Dervieux T., et al. 2019. Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate. Arthritis Rheumatol.

ACR. 2018. Diagnostic Performances of Antibodies Against Carbamylated Proteins in U.S. Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases.

ACR. 2017. Complement Activation in Peripheral Blood in Relation to lupus, Antiphospholipid and Rheumatoid Arthritis Autoantibodies: Insights From Clinical Laboratory Evaluations.

ACR. 2017. Cell bound Complement Activation Products Distinguish systemic lupus erythematosus From Other Diseases Among Patients With High Antinuclear Antibody Titers and Normal Complement.